Abstract
Treatment of patients with Type 1 diabetes with continuous subcutaneous insulin infusion (CSII) was re-introduced in Denmark in this millennium and initiated in the diabetes clinic, Fredericia Hospital, in 2005. The aim of the present study was to present yearly data of quality from 2005 to 2013 from a clinical database of patients treated with CSII in routine practice. Methods: A database was established in 2009-2010. Data from 2005 to 2009 are retrospective, data from 2009 to 2013 prospective. From 2009, patient satisfaction was measured by validated questionnaires. Results: By 31 December 2013, the database contained data from 143 active patients. HbA1C (median and range) decreased from 64 (40 - 126) mmol/mol (8.0 (5.8 - 13.7)%) (n = 104) to 60 (36 - 98) mmol/mol (7.6 (5.4 - 11.1)%) (n = 134) (p < 0.001) before and latest year on CSII. The improved glycaemic control was maintained each year until ≥5 years after initiation of CSII (p < 0.01). There was no change in weight. The number of attacks of severe hypoglycaemia was reduced from 60 attacks in 21 patients (n = 104) the year before CSII to only 5 attacks in 5 patients in 2013 (n = 134) (p < 0.01), corresponding to an incidence of 3.7 episodes per 100 patient years. Each year after initiation of CSII until ≥5 years, the number of episodes of severe hypoglycaemia was reduced (p < 0.01). Since 2005, nine episodes of ketoacidosis have been registered in eight patients corresponding to an incidence of 1.4 episodes per 100 patient years. Patient satisfaction was high one year after initiation of CSII (p < 0.01). Conclusion: Change of treatment to CSII is accompanied by an improvement in glycaemic control, very pronounced reduction in severe hypoglycaemia, low levels of diabetic ketoacidosis, and pronounced patient satisfaction.
Highlights
Treatment with continuous subcutaneous insulin infusion (CSII) was considered to be associated with an increased risk of acute complications such as severe hypoglycaemia and diabetic ketoacidosis (DKA) [1]
The satisfaction score in favour of CSII was very high. It is more than 10 years ago that a Danish study reported very low use of CSII among Danish adult type 1 diabetic subjects [2]
We initiated treatment with CSII in 2005 and by the end of 2013 after nine years we followed 143 adult type 1 diabetic subjects treated with CSII in the diabetes clinic, Fredericia Hospital
Summary
Treatment with continuous subcutaneous insulin infusion (CSII) was considered to be associated with an increased risk of acute complications such as severe hypoglycaemia and diabetic ketoacidosis (DKA) [1]. It was more likely, that CSII was associated with better metabolic control and lower risk of severe hypoglycaemia. We initiated treatment with CSII in 2005 in the diabetes clinic in Fredericia, and data on the patients have been registered in a database. Data from the database have been reported previously [4] [5]. We report results from the database with data before and yearly until ≥5 years of pump treatment during the period 2005-2013 with focus on glycaemic control, severe hypoglycaemia, DKA, and patient satisfaction
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
